Tuesday, May 19, 2026

Skin cancer remains the most common malignancy in the United States, representing a growing clinical and public health challenge. Despite its prevalence, it is also one of the most preventable and, when detected early, highly treatable cancers. For primary care physicians (PCPs), skin cancer sits squarely within the scope of daily practice—not only because of its frequency, but also because early recognition often begins outside the dermatology office. As frontline providers, PCPs are uniquely positioned to identify suspicious lesions, stratify patient risk, initiate diagnostic workups, and coordinate care that can significantly alter patient outcomes.

The importance of this role continues to expand as incidence rates climb and as advances in diagnostics and therapeutics reshape the management landscape. Understanding the nuances of skin cancer—from early presentation to evolving treatment modalities—enables PCPs to deliver more effective, timely, and comprehensive care.

Epidemiology and Risk Factors 

The incidence of skin cancer continues to rise steadily, influenced by a combination of environmental, behavioral, and demographic factors. Increased ultraviolet (UV) radiation exposure remains the most significant contributor, whether from natural sunlight or artificial sources such as tanning beds. At the same time, an aging population has contributed to higher cumulative UV exposure across lifetimes, further elevating risk. Improved awareness and detection have also played a role, leading to more diagnoses, particularly in early-stage disease. 

Risk factors are multifactorial and often cumulative. Patients with fair skin, light-colored eyes, and a propensity to burn rather than tan are at increased risk due to lower melanin protection against UV radiation. A history of blistering sunburns, especially during childhood, is strongly associated with melanoma risk. Chronic sun exposure, more often linked to occupational or lifestyle factors, increases the likelihood of non-melanoma skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). 

Immunosuppressed individuals—including organ transplant recipients and patients on long-term immunosuppressive therapy—are at markedly increased risk, particularly for aggressive SCC. Genetic predispositions, such as familial melanoma syndromes, and a personal history of skin cancer further compound risk. For PCPs, recognizing these risk factors during routine visits allows for targeted surveillance strategies that can significantly improve early detection.

Types of Skin Cancer 

Skin cancer is broadly categorized into melanoma and non-melanoma types, each with distinct biological behavior, clinical presentation, and prognostic implications.

Basal cell carcinoma is the most common form of skin cancer, arising from basal keratinocytes in the epidermis. It is characteristically slow-growing and rarely metastasizes, but it can be locally invasive and destructive if left untreated. Clinically, BCC often presents as a pearly or translucent papule, frequently with visible telangiectasias. Some lesions may ulcerate centrally, giving rise to the classic “rodent ulcer” appearance. 

While prognosis is excellent with appropriate treatment, delayed recognition can lead to significant morbidity, particularly when lesions occur in cosmetically or functionally sensitive areas such as the face. 

Squamous cell carcinoma arises from more differentiated keratinocytes and carries a higher risk of metastasis compared to BCC. It typically presents as a scaly, erythematous plaque or nodule, which may become hyperkeratotic or ulcerated. SCC is often associated with chronic sun exposure and may arise from precursor lesions such as actinic keratoses. 

High-risk features—including location on the ears or lips, larger size, deeper invasion, and immunosuppression—are associated with an increased likelihood of metastasis and poorer outcomes. 

Melanoma, while less common than BCC or SCC, is far more aggressive and accounts for the majority of skin cancer-related deaths. It originates from melanocytes and has a strong propensity for early metastasis. Melanoma can present in a variety of forms, including superficial spreading, nodular, lentigo maligna, and acral lentiginous subtypes. The well-known ABCDE criteria—Asymmetry, Border irregularity, Color variation, Diameter greater than 6 millimeters, and Evolution—remain a useful clinical framework for identifying suspicious pigmented lesions. However, clinicians must remain vigilant for atypical presentations, including amelanotic melanomas, which may lack pigmentation altogether.

The Critical Importance of Early Detection 

Early detection is the most significant determinant of outcomes in skin cancer, particularly for melanoma. When identified at an early, localized stage, melanoma carries an excellent prognosis, with five-year survival rates exceeding 99 percent. However, once the disease spreads regionally or distantly, survival rates decline dramatically. 

Primary care settings offer critical opportunities for early detection, often during visits for unrelated concerns. Patients may not recognize the significance of a changing lesion or may delay seeking dermatologic evaluation. In this context, even a brief visual inspection of exposed skin or a focused examination prompted by patient concern can lead to earlier diagnosis. 

While the role of universal full-body skin examinations in primary care remains debated, there is strong support for targeted screening in high-risk populations. Patients with significant risk factors benefit from regular skin evaluations, either in primary care or through referral to dermatology. Just as importantly, educating patients to perform self-examinations and report changes promptly can serve as a powerful adjunct to clinical screening.

Clinical Evaluation and Diagnosis 

Effective diagnosis begins with a thorough history and physical examination. A detailed history should explore personal and family history of skin cancer, patterns of sun exposure, use of tanning beds, and any changes in existing lesions or the appearance of new ones. Immunosuppressive conditions and medications should also be noted, as they influence both risk and management strategies. 

The physical examination should focus on identifying suspicious lesions, with attention to asymmetry, border irregularity, color variation, and changes over time. Documentation of lesion characteristics—including size, location, and morphology—is essential for monitoring and follow-up. Dermoscopy has emerged as a valuable adjunct in primary care, improving diagnostic accuracy when used by trained clinicians. It allows for visualization of subsurface structures not visible to the naked eye and can help distinguish benign from malignant lesions. 

Definitive diagnosis requires histopathologic confirmation. Biopsy remains the gold standard, and PCPs who are trained in minor dermatologic procedures can often perform this step efficiently within the primary care setting. Shave biopsies are commonly used for superficial lesions, while punch biopsies are useful for smaller or diagnostically uncertain lesions. When melanoma is suspected, excisional biopsy with narrow margins is generally preferred to ensure accurate assessment of tumor depth, which is critical for staging and management.

Advances in Diagnostic Technology 

Technological advancements are increasingly enhancing the ability of PCPs to detect skin cancer earlier and with greater accuracy. Artificial intelligence (AI)-assisted diagnostic tools are becoming more accessible, offering image analysis that can support clinical decision-making. While not a replacement for clinical judgment, these tools can serve as valuable adjuncts, particularly in settings where dermatologic expertise is limited. 

Total body photography and digital mole mapping are especially useful for patients with numerous nevi or high melanoma risk. These tools allow for longitudinal monitoring of lesions, making it easier to detect subtle changes over time. Teledermatology has also expanded access to specialist input, enabling PCPs to obtain rapid consultations and reduce delays in care. In underserved or rural areas, this approach can significantly improve diagnostic accuracy and patient outcomes.

Treatment Options 

The management of skin cancer varies depending on the type, stage, and location of the lesion, as well as patient-specific factors. For non-melanoma skin cancers such as BCC and SCC, treatment is often straightforward and highly effective when initiated early. 

Surgical excision remains the cornerstone of treatment for most lesions, offering high cure rates. In cases where tissue preservation is critical, such as lesions on the face, Mohs micrographic surgery provides precise margin control while minimizing removal of healthy tissue. Less invasive options, including cryotherapy and curettage with electrodessication, may be appropriate for select low-risk lesions. Topical therapies, such as 5-fluorouracil or imiquimod, can be used for superficial BCC or actinic keratoses, particularly when surgery is not desirable. 

Melanoma management is more complex and depends heavily on staging. Early-stage melanoma is typically treated with wide local excision, with margins determined by tumor thickness. Sentinel lymph node biopsy may be indicated to assess regional spread. In advanced disease, systemic therapies have dramatically improved outcomes. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have revolutionized the treatment of metastatic melanoma by enhancing the body’s immune response against tumor cells. Targeted therapies directed at specific mutations, such as BRAF inhibitors, offer additional options for selected patients.

The Role of Primary Care Physicians 

Primary care physicians are integral to every stage of skin cancer management, from prevention to long-term surveillance. Their role begins with patient education, emphasizing sun protection strategies that can reduce lifetime risk. Counseling on the use of broad-spectrum sunscreen, protective clothing, and avoidance of peak UV exposure is particularly important for younger patients, where behavior modification can have long-term benefits. 

In addition to prevention, PCPs are responsible for identifying high-risk individuals and implementing appropriate screening strategies. This includes determining which patients require more frequent skin examinations and ensuring that concerning lesions are evaluated promptly. Early detection often hinges on the ability of the PCP to recognize subtle changes and act decisively. 

PCPs may also manage certain low-risk skin cancers directly, particularly when trained in dermatologic procedures. This can improve access to care and reduce delays associated with specialist referral. For more complex cases, PCPs play a critical role in coordinating multidisciplinary care, ensuring that patients receive timely evaluation and treatment from dermatologists, surgeons, and oncologists. 

Long-term follow-up is another essential component of care. Patients with a history of skin cancer are at increased risk for recurrence and for developing new primary lesions. 

Ongoing surveillance, combined with reinforcement of preventive behaviors, helps mitigate this risk and supports better long-term outcomes.

Challenges in Primary Care 

Despite their central role, PCPs face several challenges in managing skin cancer. Time constraints during office visits can limit the ability to perform thorough skin examinations. Variability in training and comfort with dermatologic procedures may also affect diagnostic accuracy and management decisions. In some regions, limited access to dermatology services can delay referrals and treatment. 

Addressing these challenges requires a combination of continued education, adoption of new technologies, and collaborative care models. Expanding training opportunities in dermatologic evaluation and biopsy techniques can empower PCPs to take a more active role in skin cancer management. Integration of teledermatology and AI tools may further support clinical decision-making and improve access to care.

Future Directions 

The future of skin cancer management in primary care is shaped by innovation and a growing emphasis on early detection. Advances in AI and imaging technologies are likely to enhance diagnostic accuracy and streamline workflows. Non-invasive diagnostic tools, including molecular and optical imaging techniques, are under development and may reduce reliance on biopsy in the future. 

At the same time, continued progress in systemic therapies—particularly in immunotherapy—will further improve outcomes for patients with advanced disease. As these treatments become more widely used, PCPs will play an increasingly important role in managing side effects and coordinating care across specialties.

Conclusion 

Skin cancer represents a critical area of opportunity for primary care physicians to make a meaningful impact on patient outcomes. With rising incidence rates and a strong correlation between early detection and survival, the role of the PCP is more important than ever. Through vigilant clinical assessment, patient education, and appropriate use of diagnostic and referral pathways, PCPs can significantly reduce the burden of this common disease. 

In many cases, the difference between a curable lesion and a life-threatening malignancy lies in early recognition. Within the primary care setting, that recognition often begins with a single observation—one that underscores the enduring importance of clinical awareness and proactive care in modern medicine.